Search Results - immuno+oncology

18 Results

Sort By:

NKG2D-SCD-T-Engager

Therapeutics targeting NKG2D ligands for elimination of cancer cells and senescent cells A novel fusion protein targeting NKG2D ligands for eradicating cancer and senescent cells. Natural killer group 2 member D ligands (NKG2DLs) are consistently upregulated in cancer cells, senescent cells, and cells undergoing genotoxic stress. Moreover,...

Published: 5/15/2025 | Updated: 3/10/2024 | Inventor(s): Thomas Schmitt, Roland Strong

Keywords(s): Immuno Oncology

Category(s): Therapeutic

Method of adoptive T cell therapy utilizing notch signaling to enhance efficacy

Notch Activation to Improve Persistence and Efficacy of T Cell Therapies Method of using Notch ligands during culturing to improve the persistence and efficacy of CAR T cell therapies. While CAR T-based cell therapies are promising, the persistence, proliferation, and efficacy of those engineered T cell therapies need to be improved. Additionally,...

Published: 10/14/2024 | Updated: 3/10/2024 | Inventor(s): Irwin Bernstein, Stanley Riddell, Margot Pont

Keywords(s): Immuno Oncology, Target

Category(s): Therapeutic

CCNA1 TCRs

CCNA1 TCRs for AML and solid tumors High-affinity HLA-A2 restricted TCRs for the treatment of AML and several solid tumors. Cancer-testis antigen cyclin A1 (CCNA1) is an alternative A-type cyclin and is thought to promote cell proliferation (specifically at the G1/S transition) and survival, has been shown to be leukemogenic in mice....

Published: 5/15/2025 | Updated: 12/12/2023 | Inventor(s): Rachel Perret, Philip Greenberg

Keywords(s): Immuno Oncology

Category(s): Cell Therapy

Engineering B cells to obtain CD40 signals from antigen instead of CD40Ligand (CD40L)

Designing universal donor B cells that will respond to antigen independently of T cell boost Methods to link CD40 signaling to antigen binding independently of CD40L binding in order to potentiate B-cell responses. Vaccines increase immunity against infections by stimulating B cells to produce antibodies against the infectious agent. In addition...

Published: 12/6/2023 | Updated: 12/6/2023 | Inventor(s): Justin Taylor, Laila Shehata, Marti Tooley

Keywords(s): HSC Therapy, Hybridoma / Antibody, Immuno Oncology

Category(s): Therapeutic

Markers for identification and sorting of neoantigen specific CD4 T cells from solid tumors

CD4+ T cell markers, compositions, and methods for cancer therapy Markers, methods, and compositions for identifying CD4+ T cells (or T cell receptor genes thereof) with tumor antigen specificity, tumor neoantigen specificity, and/or tumor-infiltrating capacity. While cancer immunotherapies have historically focused on CD8+ T cells, tumor antigen...

Published: 12/5/2023 | Updated: 12/5/2023 | Inventor(s): Joshua Veatch, Stanley Riddell

Keywords(s): Immuno Oncology

Category(s): Cell Therapy

MHC class II restricted T cell receptors targeting mutations in EGFR

MHC class II restricted T cell receptors targeting mutations in EGFR Compositions and methods for targeting EGFR antigens (for e.g., to treat or manage cancer) Activating mutations in EGFR cause a subset of non-small cell lung cancer that occurs preferentially in women and non-smokers. EGFR mutated lung cancer responds to small molecule kinase...

Published: 12/5/2023 | Updated: 12/5/2023 | Inventor(s): Joshua Veatch, Stanley Riddell

Keywords(s): Immuno Oncology

Category(s): Cell Therapy, Therapeutic

Development of Fully Human Anti-Human Siglec-8 Antibodies as Basis for Therapeutics to Treat Eosinophilic and Mast Cell Disorders

Novel biologics targeting Siglec-8 to treat eosinophil-driven diseases Fully human mAbs, bispecific antibodies, and NK CARs that target Siglec-8. Siglec-8 is a transmembrane protein expressed on mature eosinophils, mast cells, and (to a lesser degree) basophils. Excessive eosinophil and mast cell activity have been implicated in the pathology...

Published: 2/12/2025 | Updated: 7/18/2023 | Inventor(s): Roland Walter, George Laszlo

Keywords(s): Hybridoma / Antibody, Immuno Oncology, Target

Category(s): Therapeutic

Therapeutic targeting PRAME with mTCRCAR T cells 1 in Acute Myeloid Leukemia

TCR mimic CAR T cells targeting PRAME/HLA-A2 Chimeric antigen receptor (CAR) that bind Preferentially Expressed Antigen in Melanoma (PRAME) ALYVDSLFFL (ALY) / HLA-A*0201 (HLA-A2) to treat PRAME-expressing cancers. PRAME is aberrantly expressed in childhood and adult AML and is absent in normal hematopoietic cells, providing an ideal target for...

Published: 10/14/2024 | Updated: 2/28/2023 | Inventor(s): Soheil Meshinchi, Danielle Kirkey, Anisha Loeb, Quy Le

Keywords(s): Immuno Oncology

Category(s): Therapeutic

High Affinity MAGE-A1 T-cell Receptors

TCR Cell Therapy Targeting MAGE-A1 High-affinity MAGE-A1-specific TCR for the treatment of multiple myeloma and solid tumors. The MAGE family are CTAs expressed in many tumor types and MAGE-A1 has been shown to directly drive tumorigenesis. Specifically, MAGE-A1 is expressed in about 50% of multiple myeloma, up to 60% in triple negative...

Published: 5/15/2025 | Updated: 1/19/2023 | Inventor(s): Aude Chapuis, Thomas Schmitt, Megan McAfee

Keywords(s): Immuno Oncology, Target

Category(s): Cell Therapy, Therapeutic

Chimeric and Humanized Anti-CD45 Antibody for Therapeutic Applications

Chimeric and Humanized Anti-CD45 Antibody for Therapeutic Applications Humanized antibody offers reduced toxicity and anti-mouse antibody immunization CD45 is a transmembrane cell surface glycoprotein expressed on almost all hematopoietic cells and absent on non-hematopoietic cells. CD45 is an abundantly expressed target in most hematologic...

Published: 12/6/2023 | Updated: 6/9/2022 | Inventor(s): Roland Walter, Brenda Sandmaier, David King, George Laszlo

Keywords(s): Hybridoma / Antibody, Immuno Oncology, Target

Category(s): Therapeutic

1 2